NO20012818D0 - Nye kreftbehandlinger - Google Patents

Nye kreftbehandlinger

Info

Publication number
NO20012818D0
NO20012818D0 NO20012818A NO20012818A NO20012818D0 NO 20012818 D0 NO20012818 D0 NO 20012818D0 NO 20012818 A NO20012818 A NO 20012818A NO 20012818 A NO20012818 A NO 20012818A NO 20012818 D0 NO20012818 D0 NO 20012818D0
Authority
NO
Norway
Prior art keywords
cell lines
prostate cancer
heterogeneity
cancer treatments
new cancer
Prior art date
Application number
NO20012818A
Other languages
English (en)
Other versions
NO326035B1 (no
NO20012818L (no
Inventor
Angus George Dalgleish
Peter Michael Smith
Andrew Derek Sutton
Anthony Ian Walker
Original Assignee
Onyvax Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Onyvax Ltd filed Critical Onyvax Ltd
Publication of NO20012818L publication Critical patent/NO20012818L/no
Publication of NO20012818D0 publication Critical patent/NO20012818D0/no
Publication of NO326035B1 publication Critical patent/NO326035B1/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/22Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515Animal cells
    • A61K2039/5152Tumor cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/80Vaccine for a specifically defined cancer
    • A61K2039/884Vaccine for a specifically defined cancer prostate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO20012818A 1998-12-10 2001-06-07 Allogent immunterapeutisk middel, agens, sammensetning og vaksine for behandling av prostatakreft, og anvendelse av disse. NO326035B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9827103.4A GB9827103D0 (en) 1998-12-10 1998-12-10 New cancer treatments
PCT/GB1999/004135 WO2000033870A2 (en) 1998-12-10 1999-12-09 New cancer treatments

Publications (3)

Publication Number Publication Date
NO20012818L NO20012818L (no) 2001-06-07
NO20012818D0 true NO20012818D0 (no) 2001-06-07
NO326035B1 NO326035B1 (no) 2008-09-01

Family

ID=10843925

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20012818A NO326035B1 (no) 1998-12-10 2001-06-07 Allogent immunterapeutisk middel, agens, sammensetning og vaksine for behandling av prostatakreft, og anvendelse av disse.

Country Status (19)

Country Link
US (1) US6699483B1 (no)
EP (1) EP1137434B1 (no)
JP (1) JP4607330B2 (no)
KR (1) KR100612552B1 (no)
AT (1) ATE412425T1 (no)
AU (1) AU777969B2 (no)
CA (1) CA2354046C (no)
CZ (1) CZ20012033A3 (no)
DE (1) DE69939837D1 (no)
ES (1) ES2315024T3 (no)
GB (1) GB9827103D0 (no)
HU (1) HUP0104857A3 (no)
IL (2) IL143295A0 (no)
MX (1) MXPA01005815A (no)
NO (1) NO326035B1 (no)
NZ (1) NZ512005A (no)
PL (1) PL348829A1 (no)
WO (1) WO2000033870A2 (no)
ZA (1) ZA200104163B (no)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1272617B1 (en) * 2000-04-01 2011-04-27 Onyvax Limited Prostate cell lines and their use
CA2464228C (en) 2000-10-27 2017-01-17 Immuno-Rx, Inc. Vaccine immunotherapy for immune suppressed patients
US20070025958A1 (en) 2000-10-27 2007-02-01 Hadden John W Vaccine immunotherapy
DE60326001D1 (de) * 2002-02-22 2009-03-12 Intracel Recources Llc Sterile immunogene nicht-tumorigene tumorzell-zusammensetzungen und verfahren
US7176022B2 (en) * 2002-12-20 2007-02-13 Cell Genesys, Inc. Directly injectable formulations which provide enhanced cryoprotection of cell products
US20050019336A1 (en) * 2003-07-23 2005-01-27 Dalgleish Angus George Human prostate cell lines in cancer treatment
BRPI0414014A (pt) * 2003-08-26 2006-10-24 Becton Dickinson Co métodos para distribuição intradérmica de agentes terapêuticos
EP2591786B1 (en) 2003-10-16 2017-04-12 Cancure Limited Immunomodulating compositions and uses therefor
US8257715B1 (en) 2004-08-26 2012-09-04 University Of Notre Dame Tissue vaccines and uses thereof
US20090196850A1 (en) 2005-01-06 2009-08-06 Novo Nordisk A/S Anti-Kir Combination Treatments and Methods
US8778360B2 (en) * 2005-10-27 2014-07-15 University Of Notre Dame Extracellular matrix cancer vaccine adjuvant
US9308252B2 (en) * 2005-10-27 2016-04-12 Cook Biotech, Inc. Extracellular matrix materials as vaccine adjuvants for diseases associated with infectious pathogens or toxins
US8778362B2 (en) 2005-10-27 2014-07-15 University Of Notre Dame Anti-tumor/cancer heterologous acellular collagenous preparations and uses thereof
US8802113B2 (en) * 2005-10-27 2014-08-12 University Of Notre Dame Extracellular matrix cancer vaccine adjuvant
GB0601598D0 (en) 2006-01-26 2006-03-08 Stathopoulos Apostolos Method
US9283266B2 (en) * 2008-02-28 2016-03-15 University Of Notre Dame Metastasis inhibition preparations and methods
US20110250218A1 (en) 2008-10-29 2011-10-13 Fong Lawrence H Disease-Associated Antigens and Methods of Use Thereof
JP5797190B2 (ja) 2009-05-15 2015-10-21 アイ アール エックス セーラピューティクス, インコーポレイテッド ワクチン免疫療法
US8846059B2 (en) 2009-12-08 2014-09-30 University Of Notre Dame Extracellular matrix adjuvant and methods for prevention and/or inhibition of ovarian tumors and ovarian cancer
DK2510106T3 (en) 2009-12-08 2018-05-28 Irx Therapeutics Inc PROCEDURE FOR REVERSING IMMUNE EXPRESSION OF LANGERHANS CELLS
US20110150934A1 (en) * 2009-12-18 2011-06-23 University Of Notre Dame Ovarian Tumor Tissue Cell Preparations/Vaccines for the Treatment/Inhibition of Ovarian Tumors and Ovarian Cancer
CN105850981B (zh) * 2016-04-29 2018-07-20 绍兴市人民医院 冻存肿瘤组织的方法
CN105850982B (zh) * 2016-04-29 2018-08-17 绍兴市人民医院 一种新型组织冻存液
CN114729324A (zh) * 2019-07-24 2022-07-08 斯比根公司 永生化干细胞株的制备方法及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5788963A (en) * 1995-07-31 1998-08-04 Pacific Northwest Cancer Foundation Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy
AU1355697A (en) 1995-12-28 1997-07-28 Johns Hopkins University School Of Medicine, The Allogeneic paracrine cytokine tumor vaccines
DE69721731T2 (de) * 1996-02-02 2004-03-18 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Immortalisierte menschliche prostata-epithelzellen und klone und ihre verwendungen zur untersuchung und therapie von prostata-krebs
WO2000026676A1 (en) * 1998-11-03 2000-05-11 Cell Genesys, Inc. Cancer-associated antigens and methods of their identification
GB9827104D0 (en) * 1998-12-10 1999-02-03 Onyvax Ltd New cancer treatments

Also Published As

Publication number Publication date
CZ20012033A3 (cs) 2001-10-17
PL348829A1 (en) 2002-06-17
WO2000033870A3 (en) 2000-08-17
US6699483B1 (en) 2004-03-02
CA2354046A1 (en) 2000-06-15
GB9827103D0 (en) 1999-02-03
JP2002531521A (ja) 2002-09-24
EP1137434A2 (en) 2001-10-04
HUP0104857A3 (en) 2004-04-28
IL143295A0 (en) 2002-04-21
NO326035B1 (no) 2008-09-01
AU1668700A (en) 2000-06-26
WO2000033870A2 (en) 2000-06-15
JP4607330B2 (ja) 2011-01-05
KR100612552B1 (ko) 2006-08-11
CA2354046C (en) 2011-02-15
ES2315024T3 (es) 2009-03-16
NO20012818L (no) 2001-06-07
MXPA01005815A (es) 2003-04-02
AU777969B2 (en) 2004-11-04
KR20010090873A (ko) 2001-10-19
EP1137434B1 (en) 2008-10-29
DE69939837D1 (de) 2008-12-11
NZ512005A (en) 2004-01-30
HUP0104857A2 (hu) 2002-04-29
IL143295A (en) 2006-04-10
ZA200104163B (en) 2002-02-04
ATE412425T1 (de) 2008-11-15

Similar Documents

Publication Publication Date Title
NO20012818D0 (no) Nye kreftbehandlinger
WO2004113571A3 (en) Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
MX2021005398A (es) Terapia del cancer con celulas inmunitarias anti-cd33.
MX2017015938A (es) Inhibidores de ezh2 para el tratar linfomas.
BG101284A (en) Compounds and methods for cancer treatment
DE69534946D1 (de) Verwendung von nackten Polynukleotiden zur Herstellung eines Medikaments für die Behandlung von Tumoren
MXPA03001634A (es) Polipeptido tumoral cripto.
WO2004112825A3 (en) Combinations of tumor-associated antigens for the treatment of various types of cancers
MX2009009926A (es) Anticuerpo tumor-especifico humano monoclonal.
WO2007112316A3 (en) Mycobacterial immunotherapy for cancer treatment
WO2018064588A3 (en) Tert immunogenic compositions and methods of treatment using the same
Naylor et al. Treatment of advanced melanoma with laser immunotherapy and ipilimumab
WO2003097835A3 (en) Pharmaceutical compositions for the treatment of cancer
PH12021551036A1 (en) Anti-liv1 immune cell cancer therapy
MX2021005400A (es) Terapia del cancer con celulas inmunitarias anti-ptk7.
WO2021090062A8 (en) Anti-mesothelin eribulin antibody-drug conjugates and methods of use
Gorin et al. Using α radiation to boost cancer immunity?
HUP0104568A2 (hu) Humán prosztata sejtvonalak a daganatok kezelésében
WO2000033871A3 (en) Use of human prostate tumour cell lines in cancer treatment
Yang et al. Effect of chronic endogenous antigen stimulation on CAR T cell persistence and memory formation
EP4252852A3 (en) Methods and materials for treating cancer
WO2020036646A3 (en) Cancer neoantigens and their utilities in cancer vaccines and tcr-based cancer immunotherapy
WO2003103706A3 (en) IMMUNOGENIC COMPOSITIONS
Prehn et al. Is an immune reaction required for malignant transformation and cancer growth?
JP2019513826A5 (no)

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees